NRU in Litigation
As for the Canadian reactor, AECL president and CEO Hugh MacDiarmid, says that repairing it "for Canadian patients and health care practitioners is our primary objective. We have a dedicated team working around the clock to bring the NRU back to operation as quickly and as safely as possible. However, it is a complex task with many variables."
For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
In response to this statement, MDS Nordion says it is critical that the Canadian government insist that AECL abide by what it says is a commitment to replace the NRU reactor by bringing the Maple facilities back online as soon as possible.
MDS Nordion built the twin Maple facilities for AECL and signed a contract in 1996, stating that the reactors would replace NRU. The Maples plants were scheduled to be operational in 2000, with the $145 million cost paid by MDS Nordion. However, the Canadian government and AECL idled the new plants last year, claiming they had a fatal design flaw.
Nordion argues that the flaws can be repaired. The two sides are now locked in litigation over the Maples plants.
Sources: Lantheus, DOTmed, and industry reports
Read More on DOTmed
Related DOTmed News reports about the 56th SNM annual meeting, the radiopharmaceutical shortage, and nuclear medicine topics:
Industry Sector Report: Nuclear Medicine, DOTmed Business News, June 2009, now online
New Research and Isotope Update From SNM
MO-99 Suppliers Find New Sources
SNM Outgoing President Robert Atcher Discusses Isotope Supply and Molecular Imaging
Canadian Health Minister and SNM Leaders Meet in Toronto
Medical Isotope Shortage Reaching Crisis Proportions
SNM Past President Alexander J. (Sandy) McEwan Named Special Advisor to Canada's Minister of Health
Lantheus Medical Imaging Takes Steps on Mo-99 Shortage
MDS Nordion Opens New Radiopharmaceutical Production Facility in Belgium
An Interview With Henry Wagner, M.D.